family of highly conserved proteins is not completely known, recent evidence indicates their involvement in multiple cellular processes [,3-5] such as activators of neurotransmitter synthesis, signalling molecules, tumor suppressors, and also interacting with various protein kinases, receptor proteins,
Introduction
The 14-3-3 protein belongs to a family of conserved, dimeric proteins with a monomeric molecular mass of about 30 kDa, and it is ubiquitously expressed in various mammalian tissues. [1] There are seven known mammalian 14-3-3 isotypes (β, γ, ε, ζ, η, σ, and θ/τ). [2] The highest tissue concentration of 14-3-3 proteins is found in the brain, comprising about 1% of its total soluble protein. [1] Although the function of this Development of a dot blot assay with antibodies to recombinant "core" 14-3-3 protein: Evaluation of its usefulness in diagnosis of Creutzfeldt-Jakob disease enzymes, structural and cytoskeletal proteins, proteins involved in cell cycle and transcriptional control, and proteins modulating apoptosis. The multitude of binding partners and their key roles in different physiological processes make 14-3-3 proteins an interesting target to investigate their role in pathological processes. [6] The 14-3-3 proteins have been detected in the cerebrospinal fluid (CSF) in various neurological disorders. [7] but they are more elevated in Creutzfeldt-Jakob disease (CJD). The methods of detection included qualitative study by immunohistochemistry, [8] semiquantitative evaluation by immunoblotting, [9, 10] or quantitation by immunoassays. [11, 12] CJD is a rare form of rapidly progressive neurological disorder with dementia, myoclonus, and characteristic electroencephalogram (EEG) findings. [13] Due to the few relatively specific antemortem diagnostic signs, it is difficult to distinguish the sporadic form of CJD (sCJD) from rapidly evolving Alzheimer's disease (AD) and other dementing illnesses. [14] Definitive diagnosis of CJD is possible by immunostaining for the infective prion protein (PrP Sc ) on brain tissue collected at biopsy or autopsy or immunoblot using fresh brain tissue. [15, 16] This is practiced at national CJD registries in the West and diagnosis is offered. The potential transmissibility of the disease while handling the neural tissue poses risk to the scientist/technician and the attending staff. Though the prevalence of CJD in India is found to be low in comparison to the West, [17] the cases are diagnosed with serious public health concern. The World Health Organization (WHO) has recommended detection of 14-3-3 protein in CSF in cases of rapidly progressive dementia, with clinical correlation, as a useful diagnostic marker for CJD, minimizing the need for brain biopsy.
[18] Though 14-3-3 protein as a generic protein is detected in a few other neurological disorders, it plays a role as biomarker for the diagnosis of CJD with high probability. Over the past 2-3 years, with increased awareness, more and more possible and probable cases of CJD have been referred to the CJD Registry at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, South India, seeking diagnosis, with a need to tailor the clinical and nursing management strategies. Such diagnostic testing is available currently in only a few specialized centers in the West at a high cost (100-150 USD per test) and no kit for diagnostic purpose is available for testing the patient samples in India.
The objective of the proposed study was to develop an in-house, sensitive assay for quantitation of 14-3-3 protein and evaluate its specificity and sensitivity in diagnosis of CJD (prion disease). Toward this, a minigene expressing the "core" 14-3-3 protein was synthesized by overlapping polymerase chain reaction (PCR) and the recombinant protein was produced by employing a bacterial expression system. Polyclonal antibodies were raised in the rabbit against the purified recombinant protein and used for cost-effective dot blot assay following avidin-biotin technology, using diaminobenzidine as the chromogen. This method was used for quantitation of 14-3-3 protein in CSF samples from cases of CJD and disease controls from cases of other neurodegenerative diseases such AD and Parkinson disease (PD).
Materials and Methods

Animals
New Zealand White rabbits from the Central Animal Research Facility, NIMHANS, Bengaluru, India were used for the production of polyclonal antibodies. They received pellet diet and water ad libitum. They were maintained at 12 h light and 12 h dark cycles under controlled conditions of humidity and ambient temperature. This study was approved by the Institutional Animal Ethics Committee.
Materials
Oligonucleotides were custom-synthesized by SigmaAldrich (Bengaluru, India). Deep-vent DNA polymerase, plasmid pMAL-c4X, BamH1 and EcoR1 restriction enzymes, T4 DNA ligase, amylose resin, factor Xa, and EK12 cells were purchased from New England Biolabs (Hitchin, Hertfordshire, UK). Isopropyl thiogalactoside (IPTG), avidinperoxidase, 3,3'-diaminobenzidine, gelatin, tricine, triton X-100, biotin N-hydroxysuccinimide ester, protein A-Sepharose, polyvinylidine difluoride (PVDF) membrane, Freund's Complete and Incomplete Adjuvants were procured from Sigma Aldrich (Bengaluru). Centrifugal concentrator units were purchased from Sartorius (Gottingen, Germany). All other reagents used were of analytical grade and obtained locally. CSF samples were collected into sterile tubes and placed on ice, and within 1 h of collection, frozen and preserved at −80°C until analyses were obtained from the archives of the Human Brain Tissue Repository (HBTR), NIMHANS. This study was approved by the Institutional Human Ethics Committee.
Synthesis and cloning of minigene encoding "core" 14-3-3 protein and expression of recombinant plasmid
The approach adopted in the synthesis of "core" 14-3-3 gene and the methodology followed for its expression in Escherichia coli (E. coli) was similar to that described earlier. [19, 20] For this purpose, E. coli optimized 335 nucleotide sequences encompassing the open reading frame (ORF) of core 14-3-3 was designed. The sequence was then divided into 8 primers with overlaps of 16-18 nt. The minigene was synthesized over 5 rounds of overlapping PCR. The products of each round were analyzed by 2% agarose gel electrophoresis. Bacterial cultures, plasmid purification, and transformations were performed following standard protocols. [21] After ascertaining the correct nucleotide sequence, the final PCR product was double digested with EcoR1 and BamH1 and cloned into pMAL-c4X vector. Expression of core 14-3-3 protein was achieved by transformation and induction of EK12 cells with 1 mM IPTG. Using amylose affinity chromatography, the recombinant protein was purified to homogeneity from 8M urea insoluble fraction. Vector-encoded fusion tag of the recombinant protein was cleaved by factor Xa digestion. [20] Homogeneity of the purified peptide was ascertained by tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. [22] Production of polyclonal antibodies Core 14-3-3 protein was emulsified in Freund's Complete Adjuvant and injected subcutaneously into rabbits at a dose of 1 mg per animal for primary injection. For subsequent boosters at 4-week intervals, 500 µg of the antigen emulsified in Freund's Incomplete Adjuvant was administered subcutaneously.The immune recognition patterns of the antisera were determined by direct enzyme-linked immunosorbent assay (ELISA). [23] Development of dot blot assay and its validation Toward this, immunoglobulins (IgG) were purified from antiserum by protein A-Sepharose chromatography. [24] The purified IgG were biotinylated by the N-hydroxysuccinimide coupling method. [25] In the dot blot, for the standards, "core" 14-3-3 protein [10-1.25 ng in 10 µL of phosphate-buffered saline (PBS)] was spotted on PVDF membrane, allowed to air-dry, and the unoccupied area was blocked for 3 h in 3% bovine serum albumin (BSA) in PBS. Next, the membranes were incubated with biotinylated anti-14-3-3 antibody (200 ng/mL) at 4°C overnight. The blot was washed 6 times (10 min for each change of wash) with the buffer [50 mM phosphate, pH 7.0 containing 0.25% gelatin, 1M NaCl, 0.05% triton X-100, and 1 mM thylenediaminetetraacetic acid (EDTA)]. The blots were placed in 1:1000 diluted avidin-peroxidase for 1 h at room temperature (RT) and washed again, as described earlier. The antigen-antibody complex was visualized by using 3,3'-diaminobenzidine (1 mg/mL, in 50 mM citrate buffer, pH 5.5) as the chromogen.
For the CSF samples, 1 mL of CSF was concentrated to 10 µL (100-fold) using the centrifugal concentrators, by spinning at 5000 rpm for 90 min at 4°C in a refrigerated centrifuge. The CSF sample was then loaded on PVDF membrane and processed as described above. The intensity of the color developed was quantitated by densitometric scanning and calculated from the graph constructed with the concentration of the antigen standards.
For validation of the test, CSF samples from CJD cases were retrieved from the archives of the HBTR, NIMHANS. This included 50 cases. Four were definite CJD (confirmed by immunohistochemical demonstration of PrP sc in brain tissues examined postmortem using KG9 monoclonal antibody procured from the Roslin Institute, University of Edinburgh, UK) and 46 were probable CJD, classified based on Master's criteria for diagnosis of CJD. [13] CSF samples collected from patients who were suffering from the following disorders: AD, PD, leukodystrophy, chronic alcoholism, Down syndrome, multiple sclerosis, head injury, or Wilson disease served as disease controls.
Statistical analysis
Results were analyzed with the aid of GraphPad Version 3 (Prizm; GraphPad Software Inc., San Diego, California, USA). The results were expressed as the mean ± standard error of the mean (S.E.M). The differences were analyzed using Mann-Whitney test, assuming Gaussian distribution. Differences were considered significant if P < 0.05. Standard measures of statistical significance were used to identify true-positive, true-negative, false-positive, and false-negative results. The levels of 14-3-3 in 50 CJD cases and 70 disease controls were compared using receiver operating characteristic (ROC) analysis.
Results
Choice and preparation of the antigen
For the development of dot blot method for quantitation of 14-3-3 protein, the amino acid sequence of all the seven isoforms of 14-3-3 protein were scrutinized using Clustal W program. [26] The analysis revealed the presence of 5 clusters exhibiting 100% homology among them. Next, these sequences were subjected to computer algorithm AMPHI for indicating the propensity to harbor relevant T-helper cell recognition motifs. [27] Based on these predictions, the sequences were selected for their immunogenic potential, while eliminating the irrelevant sequences from the full length 14-3-3 protein. These 5 sequences were aligned with gly-gly linker sequence [ Figure 1 ] and considered as the core protein (103 amino acids long). The synthetic gene encoding the "core" sequence of 14-3-3 protein was constructed using the overlapping PCR and the products were analyzed by 2% agarose gel electrophoresis[ Figure 2] . A stepwise elongation of the core template (83 nt) occurred after the second (153 nt), third (219 nt), and fourth (276 nt) rounds of PCR, finally yielding a 335-nt long product. The purified PCR product was cloned into pMAL-c4X vector. The DNA sequence of the recombinant plasmid revealed that the inserted sequence was appropriate and corresponded to the gene as designed. The expression of the recombinant "core"14-3-3 protein (11 kDa) was achieved by induction with IPTG as an extension of maltose binding protein (MBP) fusion protein (43 kDa) corresponding to the 54KDa band on SDS-PAGE. As the fusion protein was accumulated as insoluble aggregates, it was first solubilized in 8 M urea and further purified by passing through amylose affinity chromatography. After cleaving the fusion tag, the recombinant "core" 14-3-3 protein was analyzed by tricine-SDS-PAGE [ Figure 3 ]. The yield was about 1 mg of recombinant protein per liter of bacterial culture.
Production of polyclonal antibodies to recombinant "core" 14-3-3 protein The immune recognition pattern of the antiserum toward "core" 14-3-3 protein and the antibody titer was determined by direct ELISA [ Figure 4 ]. The dilution of peptide-specific sera at 50% Bmax was found to be approx. 1:10,000.
Quantitation of 14-3-3 protein in human CSF samples by dot blot method For the standards, "core" 14-3-3 protein was spotted (10-1.25 ng in 10 µL of PBS) on PVDF membrane for immunoblotting [ Figure 5a ]. A total of 120 samples were analyzed by this method and the data are presented in Table 1 . A representative immunostained section of the brain tissue from a definite case of CJD, with PrP Sc -specific monoclonal KG9 antibody. served as the positive reference [ Figure 5b ]. The dot blot analyses of the CSF samples from the 4 definite CJD cases are shown in Figure 5c and some of the probable CJD samples in Figure 5d , and the pattern obtained with disease controls in Figure 5e . The results obtained in the present study strongly affirm high diagnostic utility of the dot blot method with almost 10-fold difference in the levels of 14-3-3 protein between the CJD cases and controls [ Table 2 ].
For evaluating test utility, ROC analysis was carried out. The results suggested an optimal cutoff value of 2 ng/mL. Using this cutoff, we obtained a sensitivity of 100% for definite and probable cases and a specificity of 86% when other neurological disorders were considered, with a positive predictive score of 88% and a negative predictive score of 100%.
Discussion
Presence of 14-3-3 protein, as individual isoforms or as a combination of the isoforms have been reported to be a biomarker in the CSF of CJD cases, by ELISA and western blotting methods, albeit with conflicting reports. [9] [10] [11] [12] 28, 29] However, the analytic mean of the cutoff data between CJD and case controls is not very clear, often with low specificity. With a view to enhance the specificity of the 14-3-3 antiserum for selective recognition in CSF samples, we developed a solid phase immunoassay using antibodies generated against immunologically relevant "core" 14-3-3 protein. Sc in brain tissue (biopsy/autopsy) by immunohistochemical labelling using the monoclonal antibody KG9, § Probable cases: Cases with rapidly progressive dementia (aged 45-65 years), neuroimaging features, myoclonus, the exclusion of other causes including metabolic for rapidly evolving dementia, satisfying Master's criteria [13] The analysis of CSF samples using this indigenously developed method indicated a significantly higher level of 14-3-3 in definite as well as probable CJD samples, compared to the CSF from patients with other neurological disorders. These findings highlight the utility of the assay, in clinical practice for the diagnosis of CJD. The use of a core protein encompassing the epitopes shared by all the isoforms as the antigen contributed to the high specificity and sensitivity of the assay. The antibodies to this protein used in this assay detect total 14-3-3 content, recognizing the isoforms present in CSF. Although further evaluation of the 14-3-3 isoform pattern by using isoform-specific antibodies may still be required, this technique may be useful in differentiating CJD from other diseases including rapidly progressive central nervous system disorders. Because of the ubiquitous nature of 14-3-3 protein in the brain, it is expected to find traceable amounts of this protein in CSF from cases of head injury. However, this presence did not alter the specificity and sensitivity of the assay, which retained its diagnostic usefulness. Further validation of this test requires large-scale studies of larger numbers of samples.
This study has great financial implications for the patient as, at present, the analysis of 14-3-3 protein is being offered by only a few centers such as the National CJD Research and Surveillance Unit at the University of Edinburgh (http://www.cjd.ed.ac. uk/diagnosis), UK, the National Prion Disease Pathology Surveillance Center at Case Western Reserve University, Ohio (http://case.edu/med/pathology/centers/npdpsc/) USA, the Mayo Clinic, USA (www.mayomedicallaboratories.com), and the Australian National CJD Registry, Australia (http://ancjdr. path.unimelb.edu.au/diagnostic-testing/14-3-3-csf-proteintest), often at an approximate cost of 100-150 USD equivalent' per sample. In contrast, our indigenously developed 14-3-3 assay incurred the reagent cost of <20 USD equivalent. In view of this economic advantage, we are working toward offering a cost-effective, sensitive diagnostic test from the Department of Neurochemistry at NIMHANS at an affordable price, to the clinicians managing cases of CJD-prion disease. 
